Erick Moran Carreira

This inventor holds 24 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 13 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: ETH Zurich, Johnson and Johnson Vision Care, Inc., Lonza Inc.. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erick Moran Carreira. Retrieved from https://idiyas.com/inventor/erick-moran-carreira

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 24 (Patent Applications = 7)

% Patents Active = 20.8

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 13 (Patent Applications = 13)

Average Co-Inventor Count = 2.1

ph-index = 5

Forward Citations = 56(Granted Patents)

Location History:

CH-8093 Zurich, CH (2003)
Zürich, CH (2011 - 2012)
Zumikon, CH (2003 - 2022)
Zurich, CH (2010 - 2024)

Company Filing History:

Johnson and Johnson Vision Care, Inc.

Sumitomo Chemical Company, Limited

patents

5. 2 out of 2

Lipideon Biotechnology Ag

Stemergie Biotechnology Sa

patent

8. 1 out of 1

Swiss Cannapharmaceutical Sa

patent

9. 6 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

Crosslinking Reagents

Cannabinol Conversion

ROR Gamma Modulators

Mitochondrial Inhibitors

Chiral Compounds

Optically Active Hydroxy

Pharmaceutical Compositions

Photochromic Compounds

Propargylic Alcohols

Diols

Indolinospiropyran

Transition Metal Complexes

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12306180 - Tri-functional crosslinking reagents (2025-05-20),

2. 11981651 - Conversion of THC, CBD and their derivatives to Cannabinol (2024-05-14),

3. 11385225 - Tri-functional crosslinking reagents (2022-07-12),

4. 9777036 - ROR gamma modulators (2017-10-03),

5. 9766235 - Trifunctional crosslinking reagents (2017-09-19),

6. 9458174 - Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof (2016-10-04),

7. 9212175 - Pharmaceutical hypocholesterolemic compositions (2015-12-15),

8. 8969550 - Process for the synthesis of cyclic carbamates (2015-03-03),

9. 8957204 - Process for the synthesis of cyclic carbamates (2015-02-17),

10. 8283502 - Autocatalytic process for the synthesis of chiral propargylic alcohols (2012-10-09),

11. 8115032 - Process for the synthesis of a propargylic alcohol (2012-02-14),

12. 8044224 - Chiral iridium aqua complex and method for producing optically active hydroxy compound by using the same (2011-10-25),

13. 7863443 - Phosphoramidite ligand and production method of allylic amine using the same (2011-01-04),

14. 7790900 - Method for producing an optically active nitro compound (2010-09-07),

15. 7790882 - Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst (2010-09-07),

Title: **Erick Moran Carreira: A Pioneer in Cannabinoid Innovations**

Introduction

Erick Moran Carreira, based in Zumikon, Switzerland, is a leading inventor in the field of cannabinoid research, holding an impressive 23 patents. His innovative contributions reflect advancements in the understanding and application of cannabinoids, positioning him at the forefront of this rapidly evolving industry.

Latest Patents

Erick's recent patents showcase his expertise and creativity. One of his notable inventions is the method for the conversion of THC, CBD, and their derivatives to Cannabinol. This method focuses on aromatizing the alicyclic region of cannabinoids, particularly the cyclohexene group in various forms of Δ-THC and its related compounds. The process employs an oxidizing agent, specifically sulfur, to enhance the properties of these substances.

Another significant patent involves tri-functional crosslinking reagents designed for scientific applications. These reagents facilitate conjugation to target glycoproteins, allowing for improved detection, identification, and characterization of ligand-target interactions in living cells and biological fluids. This innovative approach also introduces new uses for catalysts in such detection methods.

Career Highlights

Throughout his career, Erick has contributed to influential companies, including Johnson & Johnson Vision Care, Inc. His work in these organizations has allowed him to push the boundaries of cannabinoid research and develop patents that are not only groundbreaking but also essential for future pharmaceutical applications.

Collaborations

Collaboration has been a crucial aspect of Erick's success. He has worked alongside notable colleagues, including Weili Zhao and Nicka Chinkov, fostering a creative environment that encourages the sharing of ideas and expertise. These partnerships have undoubtedly enriched his research and innovation processes.

Conclusion

Erick Moran Carreira's contributions to cannabinoid research highlight the importance of innovation in this field. With 23 patents to his name, his work continues to inspire future generations of inventors and researchers. As the industry evolves, Erick’s pioneering spirit and dedication to advancing cannabinoid applications ensure that he remains a key figure in this dynamic landscape.

Profile summary based on public USPTO records.